Nuevocor Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 29

Employees

  • Latest Deal Type
  • Series A1

  • Latest Deal Amount
  • $16M

  • Investors
  • 8

Nuevocor General Information

Description

Operator of a biotechnology firm intended to develop gene therapies for the treatment of cardiovascular disease. The company focuses on genetic cardiomyopathies characterized by aberrant mechanobiology, which seeks to treat by modulating mechanical force transduction, enabling doctors to restore cardiac function in diseased hearts.

Contact Information

Website
www.nuevocor.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1 Biopolis Drive, Amnios
  • Number 05-01
  • Singapore, 138622
  • Singapore
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • 1 Biopolis Drive, Amnios
  • Number 05-01
  • Singapore, 138622
  • Singapore

Nuevocor Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nuevocor Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A1) 03-Nov-2022 $16M Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 30-Apr-2021 Completed Pre-Clinical Trials
To view Nuevocor’s complete valuation and funding history, request access »

Nuevocor Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A1
Series A
To view Nuevocor’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Nuevocor Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology firm intended to develop gene therapies for the treatment of cardiovascular disease. The com
Biotechnology
Singapore, Singapore
29 As of 2025

Holte, Denmark
 

Lake Forest, IL
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nuevocor Competitors (84)

One of Nuevocor’s 84 competitors is ResoTher Pharma, a Venture Capital-Backed company based in Holte, Denmark.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ResoTher Pharma Venture Capital-Backed Holte, Denmark
Jaguar Gene Therapy Venture Capital-Backed Lake Forest, IL
XyloCor Therapeutics Venture Capital-Backed PA
NexImmune Formerly VC-backed Gaithersburg, MD
Minoryx Venture Capital-Backed Barcelona, Spain
You’re viewing 5 of 84 competitors. Get the full list »

Nuevocor Patents

  • 8

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 5

    Pending

  • Expiring in next 12 mo

Nuevocor Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202415588-D0 Transcriptional regulatory elements for cardiac-specific gene experssion Pending 23-Oct-2024
GB-202404416-D0 Treatment of disease Pending 27-Mar-2024
GB-202315695-D0 Treatment of cariomyopathy Inactive 13-Oct-2023
GB-202312938-D0 Treatment of disease by linc complex disruption Inactive 24-Aug-2023
GB-202216683-D0 Recombinant desmoplakins Inactive 09-Nov-2022
To view Nuevocor’s complete patent history, request access »

Nuevocor Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nuevocor Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
ClavystBio Venture Capital Minority
Boehringer Ingelheim Venture Fund Corporate Venture Capital Minority
EDBI Corporate Venture Capital Minority
Everjoy Fortune Corporation Minority
EVX Ventures Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial

Nuevocor FAQs

  • When was Nuevocor founded?

    Nuevocor was founded in 2020.

  • Where is Nuevocor headquartered?

    Nuevocor is headquartered in Singapore, Singapore.

  • What is the size of Nuevocor?

    Nuevocor has 29 total employees.

  • What industry is Nuevocor in?

    Nuevocor’s primary industry is Biotechnology.

  • Is Nuevocor a private or public company?

    Nuevocor is a Private company.

  • What is the current valuation of Nuevocor?

    The current valuation of Nuevocor is .

  • What is Nuevocor’s current revenue?

    The current revenue for Nuevocor is .

  • How much funding has Nuevocor raised over time?

    Nuevocor has raised $24M.

  • Who are Nuevocor’s investors?

    ClavystBio, Boehringer Ingelheim Venture Fund, EDBI, Everjoy Fortune, and EVX Ventures are 5 of 8 investors who have invested in Nuevocor.

  • Who are Nuevocor’s competitors?

    ResoTher Pharma, Jaguar Gene Therapy, XyloCor Therapeutics, NexImmune, and Minoryx are some of the 84 competitors of Nuevocor.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »